First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab

Blood Advances

Volumn 4, Issue 7, 2020, Pages 1307-1310

  Zhang, Xuhan ^a,b   Song, Kaidi ^a,b   Tong, Fei ^a,b   Fei, Mingming ^a,b   Guo, Hui ^c   Lu, Zhaohui ^a,b   Wang, Jinquan ^a,b   Zheng, Changcheng ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; INTERLEUKIN 6; METHYLPREDNISOLONE; MOXIFLOXACIN; THALIDOMIDE; TOCILIZUMAB; UMIFENOVIR;

ABNORMAL RESPIRATORY SOUND; ADULT; AMYLOIDOSIS; ARTICLE; CASE REPORT; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; COUGHING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FEVER; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; KIDNEY BIOPSY; LABORATORY TEST; LUNG AUSCULTATION; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PNEUMATOCELE; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME;

EID: 85083561828     PISSN: 24739529     EISSN: 24739537     Source Type: Journal    
DOI: 10.1182/bloodadvances.2020001907     Document Type: Article

References (8)

1. Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China [published online ahead of print 28 February 2020]. N Engl J Med. doi:10.1056/NEJMoa2002032.
2. Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients [published online ahead of print 13 March 2020]. Natl Sci Rev. doi:10.1093/nsr/nwaa041.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [published online ahead of print 24 February 2020]. JAMA. doi:10.1001/ jama.2020.2648.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
5. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959-970.
6. Krüttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res. 2012;32(2):60-65.
7. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739-748.
8. Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia. 2019;33(11):2695-2709.